Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Net Margin: 2009-2024

Historic Net Margin for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -39.66%.

  • Anika Therapeutics' Net Margin rose 9801.00% to 3.04% in Q3 2025 from the same period last year, while for Sep 2025 it was -16.64%, marking a year-over-year decrease of 276.00%. This contributed to the annual value of -39.66% for FY2024, which is 2593.00% up from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Net Margin is -39.66%, which was up 39.53% from -65.59% recorded in FY2023.
  • Anika Therapeutics' 5-year Net Margin high stood at 4.51% for FY2021, and its period low was -65.59% during FY2023.
  • Over the past 3 years, Anika Therapeutics' median Net Margin value was -39.66% (recorded in 2024), while the average stood at -40.08%.
  • As far as peak fluctuations go, Anika Therapeutics' Net Margin plummeted by 5,060bps in 2023, and later spiked by 2,593bps in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' Net Margin stood at -18.38% in 2020, then skyrocketed by 2,289bps to 4.51% in 2021, then plummeted by 1,950bps to -14.99% in 2022, then crashed by 5,060bps to -65.59% in 2023, then spiked by 2,593bps to -39.66% in 2024.